Immuron (ASX:IMC) recently disclosed its financial results for Q1 FY24, reporting total sales of A$1.6 million.
This encompasses all transactions from the initial three months of the fiscal year.
Immuron is an Australian biopharmaceutical company focusing on oral immunotherapy using dairy-derived anti-LPS Immunoglobulins.
Global online trading services company, Plus500:
Plus500 trading platform allows you to trade shares from all popular markets such as USA, UK, Germany and more, with leverage and low spreads. Using our advanced trading tools, you can also control your profits and losses.
Plus500AU Pty Ltd, AFSL #417727 issued by Australian Securities and Investments Commission. Based in Sydney.
Receive whispers every day in your inbox.
